Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.
REPORT DATE
SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) 10. SPONSOR/MONITOR'S ACRONYM(S)
U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012
SPONSOR/MONITOR'S REPORT NUMBER(S)
DISTRIBUTION / AVAILABILITY STATEMENTApproved for Public Release; Distribution Unlimited
SUPPLEMENTARY NOTES
ABSTRACTDetermining whether a man recently diagnosed with prostate cancer has aggressive disease requiring immediately radical therapy or indolent disease requiring a more passive watchful waiting or active surveillance approach is a current clinical challenge. This technology development study is focused on developing Magnetic Resonance -Electrical Property Tomography (MR-EPT) specifically for prostate imaging. MR-EPT is an imaging modality that may enable clinicians to image the electrical properties of prostate at near MR resolution. These electrical properties are hypothesized to provide sufficient contrast for distinguishing between aggressive and indolent prostate cancer. Much of the third year of this program has focused on additional MR-EPT image reconstruction algorithm development and optimization, experimental imaging of both simplistic and anatomically accurate phantoms, continued recruitment for ex vivo and in vivo prostate imaging, and statistical analysis of ex vivo prostate data. During this year we have demonstrated additional imaging capabilities of MR-EPT through phantom studies, have recruited and imaged the majority of our proposed ex vivo cohort of prostates, and continued recruitment for the in vivo imaging phase of this program. The no-cost-extension 6 months of the program will primarily focus on completing our in vivo data acquisition, statistical analysis of our data, and preparation of publications and proposals for follow-on more clinically focused studies.
INTRODUCTIONThis program builds off of our extensive experience in using electrical properties of prostate to distinguish malignant from benign tissues [1][2][3][4][5] and specifically stems from exciting new data published in The Prostate [6] in which we demonstrated significant electrical property differences...